Organization | Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)

Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL) Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Founded: Soria Spain (1998)

Organization Overview

First Clinical Trial

2016

NCT02849613

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Active Ingredients

Drugs in Phase 4 Trials (6)

dexamethasone (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

indocyanine green (ic-green) (1 trial)

levobupivacaine (chirocaine) (1 trial)

methylprednisolone (medrol) (1 trial)

ropivacaine (naropin) (1 trial)

Drugs in Phase 3 Trials (6)

allogeneic mesenchymal stem cells (1 trial)

autologous adipose-derived mesenchymal stem cells (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

hyaluronic acid (1 trial)

quetiapine (seroquel) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Delirium (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis, Viral, Human (Phase 4)

Stroke (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 13